SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CF Acquisition Corp. VI operates as a blank check company. It focuses on the search of companies in the financial services, healthcare, real estate services, technology and software industries. The company was founded on April 17, 2020 and is headquartered in New York, NY.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as investors digest a massive GPU services contract, with community sentiment focused on the potential for long-term growth versus concerns regarding dilution and the need for significant infrastructure financing. The stock is a top discussion point as the community debates the valuation impact of this deal and watches for potential short-squeeze activity driven by high short interest.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as the community debates whether the asset will break through the $80,000 level or face a potential rejection and pullback. Investors are closely monitoring treasury bond yields and potential government actions, with many traders discussing the prospects of a sustained rally toward new all-time highs.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors await clarity on the FDA's regulatory path for deramiocel, with many focused on the potential for a PDUFA extension following the company's submission of a major BLA amendment. Community sentiment remains highly polarized, pitting retail bulls anticipating a significant squeeze against shorts and skeptics concerned about long-term financial viability and regulatory hurdles.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is facing downward pressure amid investor concerns over its Q2 earnings, which featured revenue misses and wider-than-expected losses, though the market is actively debating the valuation of its robotics unit and the strength of its long-term AI strategy. Community sentiment remains mixed, with some retail investors viewing the pullback as a buying opportunity for a long-term play on its robotics and autonomous driving tech, while others remain skeptical due to ongoing margin challenges and poor delivery guidance.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as investors react to the company's newly established $1.59 billion USD cash pool and its ongoing accumulation strategy, with bullish community sentiment driven by Bitcoin's push toward $80,000. Traders are actively debating the stock's performance relative to Bitcoin, focusing on the potential for a short squeeze as the asset price holds momentum.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors anticipate the upcoming 80th clinical event from the REGAL Phase 3 trial, fueling buyout speculation and heavy short-covering momentum. The community is actively debating the reliability of recent reports regarding this milestone and the broader potential of its immunotherapy platform.

PDD Holdings, Inc. is a multinational commerce group that owns and operates a portfolio of businesses. The company aims to bring more businesses and people into the digital economy so that local communities and small businesses can benefit from increased productivity and new opportunities. It has built a network of sourcing, logistics, and fulfillment capabilities, that support its underlying businesses. PDD Holdings was founded by Hua Lin Cai and Zheng Huang in 2015 and is headquartered in Dublin, Ireland.

PDD Holdings Inc - ADR

Pinduoduo Inc.

PDD is trending as investors weigh strong profitability and advertising revenue growth against slowing top-line expansion and persistent regulatory and geopolitical headwinds. The community remains deeply divided, with many focusing on the company's robust cash balance and valuation, while others remain wary of long-term risks surrounding Chinese ADRs.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba shares are trending as investors weigh the potential of the company's aggressive AI-focused equity raise against broader concerns about immediate dilution and the impact of elevated infrastructure spending. The community remains divided, with some retail traders holding a bullish outlook on long-term AI integration while others express frustration over the timing of the share sale and historical price performance.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as investors gear up for the upcoming second-quarter earnings release, with significant community discussion focused on its massive commercial pipeline, potential short squeeze dynamics, and the high-conviction projections from recent analyst coverage. The stock is being closely watched for signs of execution on its GPU infrastructure deployments and whether the results can trigger a major re-rating.

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Regenxbio Inc

Regenxbio is facing intense scrutiny after the FDA issued a clinical hold on its RGX-121 gene therapy due to asymptomatic spinal MRI findings, causing shares to plunge. While the company stated it will not resubmit its marketing application in the near term, investors are debating whether the market overreacted, with many pointing to the benign nature of the findings and the ongoing progress of their Duchenne and retinal disease pipelines.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates

Exagen (XGN) delivered earnings and revenue surprises of +31.58% and +10.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%

The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Exagen (XGN) Q1 2026 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

Exagen Q1 Earnings Call Highlights

The New Spec Supercycle

Momentum traders are once again crowding into emerging growth sectors as artificial intelligence infrastructure, defense modernization, advanced medical technologies, and digital asset finance combine to create one of the market’s most aggressive speculative environments in years. Several names touched new 52-week highs Monday morning alongside major technology leaders including NVIDIA (NASDAQ:NVDA). $ODYS, $KBLB, $DGXX, $BW, $XGN, $MEHA, $NVDA

Exagen Inc. (XGN) Reports Q1 Loss, Beats Revenue Estimates

Exagen (XGN) delivered earnings and revenue surprises of +29.17% and +4.57%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

AtriCure (ATRC) Reports Break-Even Earnings for Q1

AtriCure (ATRC) delivered earnings and revenue surprises of +100.00% and +1.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Zimmer Biomet (ZBH) Q1 Earnings and Revenues Top Estimates

Zimmer (ZBH) delivered earnings and revenue surprises of +12.57% and +1.84%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Exagen Inc. (NASDAQ:XGN) Sees Large Decrease in Short Interest

Exagen Inc. (NASDAQ:XGN - Get Free Report) was the recipient of a large decline in short interest in April. As of April 15th, there was short interest totaling 729,740 shares, a decline of 52.5% from...

Exagen Inc. (NASDAQ:XGN) Given Average Recommendation of "Moderate Buy" by Analysts

Exagen Inc. (NASDAQ:XGN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the ten research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1...

Exagen, Inc. is a commercial-stage diagnostics company, which engages in transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. It operates under the Avise brand. The company was founded by Waneta C. Tuttle and Cole Harris in 2002 and is headquartered in Vista, CA.

Exagen Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.18	--	--	N/A
Q2 '26	-$0.19	-$0.13	32.09%	BEAT
Q1 '26	-$0.23	-$0.17	26.99%	BEAT
Q4 '25	-$0.19	-$0.20	-5.43%	MISSED
Q3 '25	-$0.16	-$0.31	-97.56%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings